VTGN
Vistagen Therapeutics, Inc.
Key Financials
Revenue
$-227000
↓ 229.0%
Operating Income
$-55973000
↓ 69.5%
Net Income
$-51418000
↓ 75.1%
Total Assets
$84.3M
↓ 31.8%
EPS (Diluted)
$-1.67
↓ 9.9%
Shareholders' Equity
$70.4M
↓ 38.4%
Total Liabilities
$14.0M
↑ 48.9%
Cash & Equivalents
$67.1M
↓ 43.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/19/2026 | View on SEC |
| 3 | 5/19/2026 | View on SEC |
| 8-K | 5/19/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| 8-K | 4/13/2026 | View on SEC |
| 4 | 4/9/2026 | View on SEC |
| 4 | 4/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VTGN |
| Company Name | Vistagen Therapeutics, Inc. |
| CIK | 1411685 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | NV |
| Phone | 650-577-3600 |